KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer
27 Juin 2023 - 1:05PM
Business Wire
KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or
the "Company"), a leading medical technology company focused on
the development, manufacturing, and commercialization of innovative
and easy-to-use specialty subcutaneous infusion solutions that
improve quality of life for patients, today announced the
appointment of Andrew D. C. LaFrence as its Chief Financial
Officer, effective July 10, 2023.
Andy LaFrence joins KORU Medical bringing over 39 years of
finance and accounting experience, including a track record of
successfully executing and influencing growth-oriented business and
M&A strategies, scaling businesses, developing and managing a
global team of finance and accounting professionals, as well as
leadership in tax, risk management and information technology. He
joins the Company from Vyant Bio, Inc, an innovative biotechnology
company reinventing drug discovery for complex neurodevelopmental
and neurodegenerative disorders, where he served as CFO from 2021
to 2023. Prior to that Andy held CFO roles at Surmodics, Inc.
(NASDAQ: SRDX) and several biotech and drug development companies.
Andy spent the first 26 years of his professional career at KPMG
where he led the Minneapolis office Life Sciences practice for over
10 years. Andy is a CPA with a BS in Accounting from Illinois State
University.
"I am incredibly excited to have Andy join KORU Medical as we
continue scaling our business and driving towards our Vision 2026
strategy. Andy's deep experience in medical devices and
biopharmaceuticals will provide an immediate impact as he is an
exceptionally talented professional with a proven track record of
leading companies through multiple phases of growth," said Linda
Tharby, KORU Medical's President and CEO. "As CFO, Andy will
partner with our team to advance our strategic plan and implement
processes and financial systems to support our continued growth. I
especially want to thank Tom Adams for his many contributions in
the interim CFO role. Tom’s leadership and dedication to KORU
Medical helped us to advance several key initiatives and
milestones. I look forward to Tom’s continued contributions in his
role as Vice President, Financial Planning and Analysis."
Mr. LaFrence added, "KORU Medical is a leader in the home
subcutaneous infusion market, a growing global market. As the
Company looks ahead toward growth on a global scale, I am excited
to leverage my background to help KORU Medical achieve its fullest
potential. I look forward to working with Linda and the KORU
Medical team to support driving our Vision 2026 growth strategy and
continuing to drive shareholder value."
In connection with the commencement of his employment, Mr.
LaFrence will be awarded an inducement grant of an option to
purchase 300,000 shares of the Company’s common stock at an
exercise price equal to the arithmetic mean of the high and low
prices of a share of common stock per share of the Company’s common
stock on the day before the grant date, July 15, 2023. Such option
is subject to a four-year vesting schedule with 25% of the shares
vesting on the first anniversary of the grant date and the
remaining shares vesting in equal annual installments on the
subsequent three anniversaries. The Compensation Committee of the
Company’s Board of Directors approved the award as an inducement
material to Mr. LaFrence’s employment in accordance with Nasdaq
Listing Rule 5635(c)(4).
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes
innovative and easy-to-use subcutaneous drug delivery systems that
improve quality of life for patients around the world. The FREEDOM
Syringe Infusion System currently includes the FREEDOM60® and
FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™
and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are
used for infusions administered in the home and alternate care
settings. For more information, please visit
www.korumedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230627376742/en/
Investor Contact: Greg Chodaczek 347-620-7010
investor@korumedical.com
KORU Medical Systems (NASDAQ:KRMD)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
KORU Medical Systems (NASDAQ:KRMD)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025